Abstract: A vaccine for delaying onset of or for treatment of Alzheimer's disease or an Alzheimer-related disorder in an individual comprises a therapeutically effective amount of a physiologically acceptable protofibril/oligomer comprising N-terminal truncated A?. An antibody for delaying an onset of or for treatment of Alzheimer's disease or an Alzheimer-related disorder in an individual hinds one or more truncated A? protofibrils/oligomers, but exhibits no or substantially no cross-reactivity with full length A? monomers, and optionally said antibody shows cross-reactivity to N-terminal truncated A? monomers. Methods for delaying an onset of or for treatment of Alzheimer's disease or an Alzheimer-related disorder employ the vaccine or antibody. Methods of detecting soluble N-terminal truncated amyloid-beta (A?) protofibrils/oligomers and N-terminal truncated A? monomers employ the antibody.

Abstract: Methods for detecting ?-synuclein oligomers in vivo comprise administering an antibody to an individual suspected of carrying soluble ?-synuclein, wherein the antibody is produced from a stabilized soluble ?-synuclein oligomer and is capable of binding the stabilized soluble ?-synuclein oligomer, wherein the stabilized soluble ?-synuclein oligomer has a lower formation rate to a non-soluble aggregated form than a non-stabilized soluble oligomer of the ?-synuclein, and wherein the antibody is labelled with a detectable marker; and detecting the presence of any complex formed between the antibody and soluble ?-synuclein by detection of the marker.

Abstract: Methods for detecting ?-synuclein oligomers in vivo comprise administering an antibody to an individual suspected of carrying soluble ?-synuclein, wherein the antibody is produced from a stabilized soluble ?-synuclein oligomer and is capable of binding the stabilized soluble ?-synuclein oligomer, wherein the stabilized soluble ?-synuclein oligomer has a lower formation rate to a non-soluble aggregated form than a non-stabilized soluble oligomer of the ?-synuclein, and wherein the antibody is labelled with a detectable marker; and detecting the presence of any complex formed between the antibody and soluble ?-synuclein by detection of the marker.

Abstract: Methods of treating or delaying onset of a neurodegenerative disorder with ?-synuclein pathology in an individual comprise administering an antibody which is produced from a stabilized soluble ?-synuclein oligomer and capable of binding a stabilized soluble ?-synuclein oligomer, the stabilized soluble ?-synuclein oligomer having a lower formation rate to a non-soluble aggregated form than a non-stabilized soluble oligomer of the ?-synuclein. The antibody has been collected from a non-human animal to which stabilized soluble ?-synuclein oligomer had been administered or has been produced by hybridoma technology, phage display, ribosome display, mammalian cell display or bacterial display, and the disorder with ?-synuclein pathology is characterized by deposition of Lewy bodies and Lewy neurites or is selected from the group consisting of Parkinson's disease (PD), dementia with Lewy bodies (DLB), the Lewy body variant of Alzheimer's disease, and multiple system atrophy (MSA).

Abstract: The invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof that (a) binds (i) wild-type A? 42/40 protofibril comprising N-terminal truncated A? forms and (ii) A? 42/40 Arc protofibril comprising N-terminal truncated A? forms and (b) has no or little cross-reactivity to A? 42/40 monomers. The invention further relates to a method of using such an antibody to treat Alzheimer's disease.

Abstract: The invention relates to an isolated antibody, or fragment thereof, having high affinity for human A? protofibrils. The invention further relates to compositions that include the antibody, or a fragment thereof, and a pharmaceutically acceptable buffer. The invention further relates to a method of preventing or treating Alzheimer's disease, which includes the step of administering to a patient having or suspected of having Alzheimer's disease such an antibody, or fragment thereof or a composition that includes the antibody or a fragment thereof.

Abstract: The invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof that (a) binds (i) wild-type A? 42/40 protofibril comprising N-terminal truncated A? forms and (ii) A? 42/40 Arc protofibril comprising N-terminal truncated A? forms and (b) has no or little cross-reactivity to A? 42/40 monomers. The invention further relates to a method of using such an antibody to treat Alzheimer's disease.

Abstract: Methods of treating or delaying onset of a neurodegenerative disorder with ?-synuclein pathology in an individual comprise administering an antibody which is produced from a stabilized soluble ?-synuclein oligomer and capable of binding a stabilized soluble ?-synuclein oligomer, the stabilized soluble ?-synuclein oligomer having a lower formation rate to a non-soluble aggregated form than a non-stabilized soluble oligomer of the ?-synuclein. The antibody has been collected from a non-human animal to which stabilized soluble ?-synuclein oligomer had been administered or has been produced by hybridoma technology, phage display, ribosome display, mammalian cell display or bacterial display, and the disorder with ?-synuclein pathology is characterized by deposition of Lewy bodies and Lewy neurites or is selected from the group consisting of Parkinson's disease (PD), dementia with Lewy bodies (DLB), the Lewy body variant of Alzheimer's disease, and multiple system atrophy (MSA).

Abstract: A vaccine for delaying an onset of or for treatment of an ?-synuclein-related disorder in an individual comprises a therapeutically effective amount of isolated stabilized soluble ?-synuclein oligomer having a lower formation rate to a non-soluble aggregated form than a non-stabilized oligomer of the ?-synuclein. An antibody for delaying an onset of or for treatment of an ?-synuclein-related disorder in an individual binds soluble ?-synuclein. Methods for delaying an onset of for treatment or for prevention of an ?-synuclein-related disorder employ the vaccine or antibody. Methods of detecting ?-synuclein oligomers employ the antibody.

Abstract: The invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof that (a) binds (i) wild-type A? 42/40 protofibril comprising N-terminal truncated A? forms and (ii) A? 42/40 Arc protofibril comprising N-terminal truncated A? forms and (b) has no or little cross-reactivity to A? 42/40 monomers. The invention further relates to a method of using such an antibody to treat Alzheimer's disease.

Abstract: The invention pertains to a method of measuring A? protofibrils in a sample. The method includes the steps of (a) providing a labeled monoclonal antibody or fragment thereof that binds wildtype A? 42/40 protofibril and A?42/40 Arc protofibril and has no or little cross-reactivity to A? 42/40 monomers with an agent that generates a measurable signal, (b) contacting said labeled antibody or fragment thereof with the fluid or tissue having or suspected of comprising A? protofibrils, and (c) measuring the amount of protofibrils bound to the antibody by measuring the signal generated by the agent.

Abstract: The invention pertains to a method of measuring A? protofibrils in a sample. The method includes the steps of (a) providing a labeled monoclonal antibody or fragment thereof that binds wildtype A? 42/40 protofibril and A?42/40 Arc protofibril and has no or little cross-reactivity to A? 42/40 monomers with an agent that generates a measurable signal, (b) contacting said labeled antibody or fragment thereof with the fluid or tissue having or suspected of comprising A? protofibrils, and (c) measuring the amount of protofibrils bound to the antibody by measuring the signal generated by the agent.

Abstract: A vaccine for delaying onset of or for treatment of Alzheimer's disease or an Alzheimer-related disorder in an individual comprises a therapeutically effective amount of a physiologically acceptable protofibril/oligomer comprising N-terminal truncated A?. An antibody for delaying an onset of or for treatment of Alzheimer's disease or an Alzheimer-related disorder in an individual binds one or more truncated AO protofibrils/oligomers, but exhibits no or substantially no cross-reactivity with full length A? monomers, and optionally said antibody shows cross-reactivity to N-terminal truncated A? monomers. Methods for delaying an onset of or for treatment of Alzheimer's disease or an Alzheimer-related disorder employ the vaccine or antibody. Methods of detecting soluble N-terminal truncated amyloid-beta (A?) protofibrils/oligomers and N-terminal truncated A? monomers employ the antibody.

Abstract: The invention relates to an isolated antibody, or fragment thereof, having high affinity for human A? protofibrils. The invention further relates to compositions that include the antibody, or a fragment thereof, and a pharmaceutically acceptable buffer. The invention further relates to a method of preventing or treating Alzheimer's disease, which includes the step of administering to a patient having or suspected of having Alzheimer's disease such an antibody, or fragment thereof or a composition that includes the antibody or a fragment thereof.

Abstract: The invention pertains to the development of antibodies that specifically bind amyloid beta protein (Abeta) in its protofibril conformation. The invention also comprises methods of using anti-Abeta protofibril antibodies to diagnose or treat Alzheimer's disease, Down's syndrome Lewybody dementia, vascular dementia, and other neurodegenerative disorders. Furthermore, the invention pertains to the use of anti-Abeta protofibril antibodies to screen and identify substances that will modulate protofibril activity or formation in vitro or in vivo. The invention also pertains to methods for synthesising pure Abeta protofibril antigens as well as to a method for stabilising Abeta protofibrils antigens as well as to a method for stabilising Abeta protofibrils.

Abstract: The present invention pertains to the prevention, treatment and diagnosis of neurodegenerative diseases, in particular Alzheimer's disease, and other similar disease. More specifically to high affinity antibodies selective for amyloid beta protein (A?) in its protofibril conformation and of IgG class and IgG1 or IgG4 subclass or combinations thereof or mutations thereof, retaining high Fc receptor binding and low C1(C1q) binding, effective in clearance of A? protofibrils and with reduce risk of inflammation.

Abstract: A vaccine for delaying an onset of or for treatment of an ?-synuclein-related disorder in an individual comprises a therapeutically effective amount of isolated stabilized soluble ?-synuclein oligomer having a lower formation rate to a non-soluble aggregated form than a non-stabilized oligomer of the ?-synuclein. An antibody for delaying an onset of or for treatment of an ?-synuclein-related disorder in an individual binds soluble ?-synuclein. Methods for delaying an onset of for treatment or for prevention of an ?-synuclein-related disorder employ the vaccine or antibody. Methods of detecting ?-synuclein oligomers employ the antibody.

Abstract: The invention relates to a device for positioning the tongue for the treatment of disorders including snoring and obstructive sleep apnoea (OSA) and OSA Syndrome, comprising an anchoring body (10) and means (13, 14, 15, 16, 17, 18) for retracting the tongue, said means being connected to said anchoring body. The tongue retracting means comprises at least two elongated arms arranged on a respective side of said anchoring body, and extending along different sides of the midline of the tongue. There is also provided a method of preventing Obstructive Sleep Apnea (OSA), comprising attaching tongue retracting means to permanently attached members in the tongue of a patient suffering from OSA at positions posterior of the tongue tip (apex), preferably to the corpus lingua and/or tongue root (radix lingua), said retracting means being anchored to structures in the mouth such as the jaws or teeth, whereby the tongue is directly held in a forward position.

Abstract: A transgenic non-human animal expressing at least one transgene including a DNA sequence encoding a heterologous Amyloid Precursor Protein (APP) including at least the Arctic mutation (E693G) and a further AD (Alzheimer's disease) pathogenic mutation or a further transgene affecting AD pathogenesis, which results in increased amounts of intracellular soluble A aggregates, including A peptides. The method of producing the transgenic animal, and methods of screening for therapeutic or diagnostic agents useful in treatment or diagnosis of Alzheimer's disease are also disclosed.

Abstract: The present invention pertains to the prevention, treatment and diagnosis of neurodegenerative diseases, in particular Alzheimer's disease, and other similar disease. More specifically to high affinity antibodies selective for amyloid beta protein (A?) in its protofibril conformation and of IgG class and IgG1 or IgG4 subclass or combinations thereof or mutations thereof, retaining high Fc receptor binding and low C1(CIq) binding, effective in clearance of A? protofibrils and with reduce risk of inflammation.